title: Successful use of the total artificial heart as a bridge to transplantation with no mediastinitis.
abstract: High rates of infection, especially mediastinitis, have been reported with the use of the total artificial heart (TAH), thereby limiting its usefulness. We have used the TAH as a bridge to transplantation with only minor infectious complications and a zero incidence of mediastinitis. Between February 1988 and August 1990, the TAH was inserted at Loyola University Medical Center in 19 patients, ages 16 to 64 years (mean, 44 years). Seventeen patients (89%) underwent transplantation within 1 to 34 days (mean, 9.8 days). Of the patients who did not undergo transplantation, one was brain dead and the other died of bleeding diathesis. Early (30-day) deaths occurred in two patients (11.7%): acute rejection at 18 days and multiple cerebral infarcts at 14 days. Three late deaths (17.6%) occurred: one patient, cytomegalovirus and pneumocystis pneumonia at 4 months; one patient, bronchopneumonia and multisystem failure at 9 months; and one patient, chronic rejection at 14 months. Minor infectious complications during the TAH implantation included Enterobacter pneumonia treated with antibiotics and positive sputum cultures (Escherichia coli; Candida), with no clinical evidence of infection in two patients. No cases of mediastinitis occurred either while the TAH was implanted or after transplantation. All patients were on antibiotics while the device was in place.
  
  
  CONCLUSIONS
  Our experience with the TAH shows this to be an excellent device for successful bridging of patients for heart transplantation. We have had minimal infectious complications and none directly attributed to the use of this device. This device should continue to be used safely as a bridge to transplantation.
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, Ill. 60153.
authors.forename: V A
authors.initials: VA
authors.lastname: Lonchyna
authors.forename: R
authors.initials: R
authors.lastname: Pifarre
authors.forename: H
authors.initials: H
authors.lastname: Sullivan
authors.forename: A
authors.initials: A
authors.lastname: Montoya
authors.forename: M
authors.initials: M
authors.lastname: Bakhos
authors.forename: J
authors.initials: J
authors.lastname: Grieco
authors.forename: B
authors.initials: B
authors.lastname: Foy
authors.forename: B
authors.initials: B
authors.lastname: Blakeman
authors.forename: R
authors.initials: R
authors.lastname: Altergott
authors.forename: D
authors.initials: D
authors.lastname: Calandra
mesh_terms: D000328:Adult; D001424:Bacterial Infections / Q000453:epidemiology* / Q000517:prevention & control; D002437:Cefazolin / Q000627:therapeutic use; D005260:Female; D016027:Heart Transplantation; D006354:Heart, Artificial; D006801:Humans; D015994:Incidence; D008297:Male; D008480:Mediastinitis / Q000453:epidemiology* / Q000517:prevention & control; D011183:Postoperative Complications / Q000453:epidemiology* / Q000517:prevention & control; D013997:Time Factors; D014640:Vancomycin / Q000627:therapeutic use
chemical_list: D014640:Vancomycin; D002437:Cefazolin